Page 194 - CW E-Magazine (14-11-2023)

Special Report

the industry has responded in kind with
a wave of facility expansions.

Year-to-year, while the numbers
vary, we continue to see and would
expect that this cyclical constraint and
loosening to continue and view it as a
status quo for the industry. However,
more so now than in the decade prior,
the type and scale of capacity being
installed will also be important, as the
demand for a significant portion of the
Fig. 6: Percentage and scale of Future bioreactors products in mid- to-late-stage develop-

be online between 2022 and 2027 at city is currently able to meet the manu- ment (met with 5,000-L of capacity or
the < 2,000, 2,000, 5,000, 10,000 and facturing demand for these products, less) has increased over time. While the
> 10,000-L scale (Figure 6), it is evi- but control and location of capa- remaining products will require larger
dent that during this time span an aver- city can affect accessibility. While the capacity to meet future demand, the in-
age of 50% of the bioreactors will be majority of capacity is product-based, dustry has responded to this demand as
at the 2,000-L scale with nearly 20% rather than CMO-based, contract evidenced by the majority of new biore-
at a scale of 10,000-L or greater. While manufacturers are significantly ex- actors are smaller in scale yet has con-
manufacturers understand the capa- panding their capacities which, in the tinued to meet the need for large scale
city demand scenarios and are install- coming years, may lessen the difficul- capacity for legacy and novel products
ing capacity to meet these anticipated ties companies without capacity may with potentially high yearly demands.
demands, it is likely that the current have experienced accessing capacity We will continue to monitor the current
and future state of the supply and demand
and future demand for a certain subset at the right time and under the right for mammalian-based biopharma-
of product will likely continue to add terms. ceuticals and will continue to track
pressure to manufacturing networks how the industry is responding and ris-
with large scale capacity. While the supply of capacity will in- ing to the challenge to meet the typical
crease over the next five years, demand and additional demands for capacity,
Overall, we predict that the bio- for capacity, is projected to increase at without creating a significant situation
pharmaceutical industry will continue higher rate. In prior years we have noted of over-capacity, as it is critically im-
to have strong growth for the foresee- both periods of capacity constraints portant to ensure current and future
able future, and that antibody pro- at the clinical scales due to very high products are available to patients.
ducts will continue to be the dominant clinical demand, as well as short-term
driver of this growth. Installed capa- loosening of capacity constraints, and [Source: CPHI Annual Report 2023]

Target Your Market More Effectively

IndiaChemTrade
Free for subscribers of Chemical Weekly
IndiachemTrade provides consolidated trade statistics of India. The information provided here is based on
the annual trade data published by the Directorate General of Commercial Intelligence and Statistics, Government of India. The
database can be searched by: Chemical Name/Harmonised Code to obtain the consolidated trade (import or export) in that item; or
by Country to obtain the trade (import or export) in all chemicals and related products between India and that country.
ChemXchange
Open to all – no subscription required
chemXchange – the chemical exchange with a difference – is where you can identify your buyers and supplyers on-line, any time.
Listing in this unique platform is free to all advertisers in the print version of Chemical Weekly for a period of 12 months.
For more information contact: 022-24044471 / 72
Email: corporate@chemicalweekly.com or log on to chemicalweekly.com

194 Chemical Weekly November 14, 2023

Contents Index to Advertisers Index to Products Advertised